The latest report by IMARC Group, titled “Meningococcal Vaccines Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2032“, The global meningococcal vaccines market size reached US$ 3.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 7.2 Billion by 2032, exhibiting a growth rate (CAGR) of 7.7% during 2024-2032.
Meningococcal vaccines are essential immunizations designed to protect individuals from bacterial infections caused by Neisseria meningitidis, commonly known as meningococcal bacteria. These vaccines safeguard public health by preventing life-threatening illnesses such as meningitis and septicemia. There are several types of meningococcal vaccines available, with the most common being the conjugate vaccines and the serogroup B vaccines. Additionally, conjugate vaccines are highly effective and target specific strains of meningococcal bacteria, including A, C, W, and Y, which are typically administered to adolescents and young adults. Serogroup B vaccines are developed to combat meningococcal serogroup B infections, responsible for outbreaks in various regions, and offer protection to individuals at higher risk. Nowadays, meningococcal vaccines work by stimulating the immune system to generate antibodies against the bacteria, thereby preventing infection.
Meningococcal Vaccines Market Trends and Drivers:
The market for meningococcal vaccines is primarily driven by the growing awareness of meningococcal diseases among the general population and healthcare professionals. In addition, meningococcal diseases caused by the Neisseria meningitidis bacteria can lead to severe health complications, including meningitis and septicemia, thus influencing market growth. Moreover, the pharmaceutical industry has made substantial progress in developing more effective and safer meningococcal vaccines, including the development of conjugate vaccines that provide longer-lasting immunity and broader protection against multiple strains of the bacteria, representing another major growth-inducing factor. Along with this, companies are investing in research and development (R&D) efforts, leading to the introduction of new vaccines and increased competition, thus propelling market growth. Besides this, the increasing improvements in healthcare infrastructure and easy access to medical services in developing countries led to the growth of the meningococcal vaccine market, thus accelerating the market growth.
For an in-depth analysis, you can refer sample copy of the report: https://www.imarcgroup.com/meningococcal-vaccines-market/requestsample
Report Segmentation:
The report has segmented the market into the following categories:
Breakup by Vaccine Type:
- Conjugate
- Polysaccharide
- Subcapsular
Breakup by Composition:
- Mono Vaccines
- Combination Vaccines
Breakup by Vaccine Serotype:
- MenACWY
- MenB & Manic
- MenC
- MenA
- MenAC
- Others
Breakup by Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Institutional Sales
- Others
Breakup by End User:
- Pediatric
- Adult
Market Breakup by Region:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
Competitive Landscape with Key Player:
- GlaxoSmithKline Plc
- Hualan Biological Engineering Inc.
- Incepta Pharmaceuticals Limited
- Novartis AG
- Pfizer Inc.
- Sanofi S.A.
- Serum Institute of India Ltd.
- Walvax Biotechnology Co. Ltd.
Note: If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.
Contact Us:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145 |United Kingdom: +44-753-713-2163
